Time to ‘Rethink’ Immunotherapy for Molecularly Driven NSCLC – Medscape
Medscape |
Time to 'Rethink' Immunotherapy for Molecularly Driven NSCLC
Medscape West: One concept that we have come to an early conclusion on has been immunotherapy in patients with EGFR mutations or ALK rearrangements. Based on the early work with monotherapy in the second-line setting, we have seen that the subgroup of … |
